IL0010951403
© Globe Newswire
30.12.2025
SPRC
LISTED
NASDAQ
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
News Preview
TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of a...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2025
SPRC
LISTED
NASDAQ
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
News Preview
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of ap...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
SPRC
LISTED
NASDAQ
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
News Preview
TEL AVIV, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., recently announced the signing of a binding term sheet to acquire treasury of patents, trademarks and intellectual...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
26.11.2025
SPRC
LISTED
NASDAQ
SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
News Preview
TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., today announced the signing of a binding term sheet to acquire a treasury of patents, trademarks and intellectual p...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
20.11.2025
SPRC
LISTED
NASDAQ
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
News Preview
TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interes...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.10.2025
SPRC
LISTED
NASDAQ
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
News Preview
TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMN...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
SPRC
LISTED
NASDAQ
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
News Preview
According to the agreement, SciSparc’s pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
SPRC
LISTED
NASDAQ
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
News Preview
TEL AVIV, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the entry into a framework agreement for mutual termination of merger, dated Oc...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
SPRC
LISTED
NASDAQ
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
News Preview
TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that on September 25, 2025, the stockholders of N2OFF, Inc. (NASDAQ: NITO) (“...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
SPRC
LISTED
NASDAQ
SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery
News Preview
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the board of directors resolved to initiate the launch of an innovative i...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2025
SPRC
LISTED
NASDAQ
SciSparc: AutoMax’s Shareholders Approve Merger with SciSparc
News Preview
TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that AutoMax Motors Ltd. ("AutoMax"), a leading parallel vehicle importer in I...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
SPRC
LISTED
NASDAQ
SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC
News Preview
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces additional progress in connection with the proposed merger with AutoMax Motors Ltd.,...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
30.07.2025
SPRC
LISTED
NASDAQ
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
News Preview
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMN...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.06.2025
SPRC
LISTED
NASDAQ
SciSparc Announces 1-for-21 Reverse Share Split
News Preview
Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
SPRC
LISTED
NASDAQ
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
News Preview
SciSparc will sell its MitoCareX’s shares for $700,000 and exchange its remaining shares for common stock in N2OFF...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
SPRC
LISTED
NASDAQ
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
News Preview
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has reached an important settlement agreement (the “Settlement”) regarding...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.02.2025
SPRC
LISTED
NASDAQ
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
News Preview
TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
SPRC
LISTED
NASDAQ
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
News Preview
TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that MitoCareX Bio Ltd. (“MitoCareX”), its joint venture with Dr. Alon Silberman,...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.12.2024
SPRC
LISTED
NASDAQ
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
News Preview
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the renewal of its approval from the Israeli Medical Cannabis Agency ("IMCA") at t...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.12.2024
SPRC
LISTED
NASDAQ
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
News Preview
TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2024
SPRC
LISTED
NASDAQ
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
News Preview
FDA confirms that SciSparc’s study may proceed only a month after application submission...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
SPRC
LISTED
NASDAQ
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
News Preview
The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc’s initial investment in MitoCareX Bio...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
SPRC
LISTED
NASDAQ
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
News Preview
FDA confirms that SciSparc’s study may proceed following the application submission a month ago...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2024
SPRC
LISTED
NASDAQ
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
News Preview
Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2024
SPRC
LISTED
NASDAQ
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
News Preview
This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2024
SPRC
LISTED
NASDAQ
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
News Preview
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
SPRC
LISTED
NASDAQ
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
News Preview
TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicin...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.08.2024
SPRC
LISTED
NASDAQ
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
News Preview
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
SPRC
LISTED
NASDAQ
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
News Preview
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center, Jerusalem, Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of the IASLC...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2024
SPRC
LISTED
NASDAQ
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
News Preview
The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.08.2024
SPRC
LISTED
NASDAQ
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
News Preview
SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.08.2024
SPRC
LISTED
NASDAQ
SciSparc Updates Regarding the Status of the AutoMax Merger
News Preview
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court’s approval of AutoMax’s petition to convene special class meetings of its shareholders to approve the Merger with the Company...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2024
SPRC
LISTED
NASDAQ
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
News Preview
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
SPRC
LISTED
NASDAQ
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
News Preview
SciSparc will receive additional payments and execution fees if certain milestones are met...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
SPRC
LISTED
NASDAQ
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
News Preview
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system (the “Company” or “SciSparc”), today announced it has received a written notice (the “Notice”) from Nasdaq S...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
SPRC
LISTED
NASDAQ
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
News Preview
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional patent application with the United States Patent and...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.05.2024
SPRC
LISTED
NASDAQ
SciSparc Secures Strategic Advantage with Grant of European Patent
News Preview
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the European Patent Office granted the Company’s patent appl...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
